Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings

Constant technological advancement enabled the production of therapeutic monoclonal antibodies (mAbs) and will continue to contribute to their rapid expansion. Compared to small-molecule drugs, mAbs have favorable characteristics, but also more complex pharmacokinetics (PK), e.g., target-mediated no...

Descripción completa

Detalles Bibliográficos
Autores principales: Germovsek, Eva, Cheng, Ming, Giragossian, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463036/
https://www.ncbi.nlm.nih.gov/pubmed/34530672
http://dx.doi.org/10.1080/19420862.2021.1964935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463036/
https://www.ncbi.nlm.nih.gov/pubmed/34530672
http://dx.doi.org/10.1080/19420862.2021.1964935

Ejemplares similares